EGFR and non-small cell lung carcinoma: Crich and coworkers31 reported a highly selective, orally bioavailable, brain penetrating EGFR-TKI 2 containing trisubstituted hydroxylamine groups (Figure 3), used in the treatment of central nervous system metastasis of NSCLC.